Abstracts

972 – Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial

Background People with HIV (PWH) have impaired Mycobacterium tuberculosis (Mtb)-specific T cell responses, making induction of effective immunity challenging. Whether TB preventive therapy (TPT) modifies Mtb-specific T cell profile in PWH is unknown. We interrogated Mtb antigen-specific T cell responses in PWH with latent TB infection (LTBI) pre- and post-TPT within the ACTG A5279 clinical…

965 – Diagnostic Accuracy of the FujiLAM Assay to Detect Tuberculosis in Advanced HIV

Background An urgent need exists for non-sputum based point-of-care diagnostics to detect tuberculosis (TB) among people with advanced HIV disease. The Fujifilm SILVAMP TB LAM (FujiLAM) is a novel point-of-care assay that detects mycobacterial lipoarabinomannan (LAM) antigen in urine to identify TB. We present a validation of the updated FujiLAM assay on prospectively collected urine…

943 – Autoantibody Prevalence After SARS-CoV-2 Infection: Comparing Baltimore, USA, and Rakai, Uganda

Background Autoantibodies (AAbs), particularly those targeting type 1 interferon subtype alpha (aIFNα), nuclear antigens (ANAs), cardiolipin (aCL), and beta 2 glycoprotein 1 (aβ2GP1), have been associated with the severity of acute COVID-19. Whether SARS-CoV-2 induces these AAbs, however, and whether there are differences across settings, remains underexplored. We investigated AAbs prevalence and induction in individuals…

981 – Recent Trends in Opportunistic Infections at ART Initiation in the NA-ACCORD of IeDEA, 2017-2021

Background Understanding the prevalence and consequences of opportunistic infections (OIs) at antiretroviral therapy (ART) initiation remains critical for informing HIV testing and care strategies that reduce the likelihood of late presentation for care. We assessed trends in OIs at ART initiation and their association with 1-year survival in the North American AIDS Cohort Collaboration on…

956 – NAT-2 Polymorphism and Risk of Antituberculosis-Induced Hepatotoxicity in Thai People With HIV

Background The NAT2 slow acetylator phenotype is associated with a higher risk of isoniazid-induced hepatitis. There is a high prevalence of slow acetylators in the Thai population. This study aimed to explore the link between NAT2 genotypes and hepatitis risk in Thai people living with HIV (PLWH) after initiating isoniazid containing regimens for TB preventive therapy (TPT) or TB treatment.  Methods A…